Biotech Values

[iwfal]

Valley of death to Precision Drugs:

Precision medicine is killing oncology as a viable investment because it requires new drugs to target smaller and smaller niches of already rare subsets of tumors. It's great for patients but the types of tumor-agnostic agents that make enough money to justify development costs are going to be few and far between.

I’d suggest it’s essentially all of drugs, not just oncologist drugs. See thread I did below, with a rebuttal at the end that I still need to think through.

Delayed response to figure out how to communicate diff of opinion:

Suggest the problem is there is a Valley of Death btwn where we are now (ethnic subgroups, v poor GRS) and full GRS for both risk and treatment. 1/n

— Clark H (@Clarksterh) May 19, 2023

Moving through this valley will require a lot more investment in understanding etiology (eg polygenic risk scores). And this will, in turn, require acknowledging things people very much do NOT want to acknowledge (eg see whole ‘debate’ on eGFR).